论文部分内容阅读
据2003年我国心力衰竭(心衰)流行病学调查资料显示,在35～74岁人群中,心衰的患病率为0.9%,据此,我国应有400～500万心衰患者[1]。心衰的药物治疗已取得长足的进展,但对存在心脏失同步化的心衰患者抗心衰药物常难于取得疗效,而心脏同步化治疗(cardiac resynchronization therapy
According to the epidemiological survey of heart failure (heart failure) in China in 2003, the prevalence of heart failure in the population aged 35-74 was 0.9%. Therefore, there should be between 400 and 500 million people with heart failure [1 ]. Good progress has been made in the treatment of heart failure. However, it is often difficult to obtain anti-heart failure drugs in patients with heart failure who have cardiac dysfunction. Cardiac resynchronization therapy